ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2026.05.015
Efficacy and Safety Analysis of Sintilimab Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
Fushuang Qiao
1School of Clinical Medicine, Chengdu Medical College, Chengdu 610500, Sichuan, China.
2Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Sichuan, China.
3Key Laboratory of Geriatric Respiratory Diseases of Sichuan Higher Education Institutes, Chengdu 610500, Sichuan, China.
*Corresponding author: Fushuang Qiao
Published: May 25,2026
Abstract
Objective: Taking the clinical treatment of advanced non-small cell lung cancer (NSCLC) as the research starting point, this study explores the practical application value of sintilimab combined with chemotherapy. Methods: The study was conducted from December 2024 to December 2025. A total of 86 NSCLC pa-tients at stage ⅢB-Ⅳ were selected from our hospital and randomly divided into two groups. The reference group (43 patients) received conventional chemotherapy, while the observation group (43 patients) received sintilimab in addition to the chemotherapy. After four treatment cycles, the clinical efficacy, serum tumor marker levels, and safety were compared between the two groups. Results: The objective response rate (ORR) and disease control rate (DCR) in the observation group were significantly higher than those in the reference group (P < 0.05). The levels of neuron-specific enolase (NSE), carbohydrate antigen 19-9 (CA19-9), and squamous cell carcinoma-related antigen (SCC-Ag) in the observation group were significantly lower than those in the reference group (P < 0.05). There was no significant difference in chemotherapy-related hematological and gastrointestinal adverse reactions between the two groups (P > 0.05). Conclusion: Based on the actual situation of patients with stage ⅢB-Ⅳ advanced NSCLC, combining sintilimab with platinum-based double-drug chemotherapy can significantly improve clinical efficacy, reduce tumor marker levels, and has controllable safety, making it worthy of promotion.
Keywords
Sintilimab; chemotherapy; advanced non-small cell lung cancer; clinical efficacy; safety
References
[1] Hong DZ, Hu TT. Effects of sintilimab combined with cisplatin and gemcitabine on objective response rate, quality of life, and progression-free survival in patients with advanced non-small cell lung cancer. Med Inf. 2025;38(24):162-165.
[2] Zhu QN. Effects of sintilimab combined with cisplatin and paclitaxel on tumor markers and quality of life in patients with advanced non-small cell lung cancer. Med Inf. 2025;38(23):126-130.
[3] Li LJ, Liu C. Therapeutic effects of sintilimab combined with docetaxel and cisplatin chemotherapy regimen on patients with advanced non-small cell lung cancer. J Chronic Dis. 2025;26(11):1670-1673. DOI:10.16440/J.CNKI.1674-8166.2025.11.18.
[4] Sun SQ. Efficacy analysis of sintilimab combined with chemotherapy in the treatment of advanced non-small cell lung cancer. China Pract Med. 2025;20(20):115-118.
DOI:10.14163/j.cnki.11-5547/r.2025.20.032.
[5] Yang P, Weng H, Ye L, et al. Clinical effects and safety of sintilimab combined with chemotherapy drugs in the treatment of advanced non-small cell lung cancer. Pract J Integr Tradit West Med. 2024;24(18):20-22,30.
DOI:10.13638/j.issn.1671-4040.2024.18.006.
[6] Wang ZW, Zhu QQ, Li MY, et al. Analysis of the impact of sintilimab combined with chemotherapy on the prognosis of patients with advanced non-small cell lung cancer. China Rational Drug Use Explor. 2023;20(8):71-77.
[7] Chen LX, Sun P, Hu ZZ. Effects of sintilimab combined with chemotherapy on tumor markers and immune function in patients with advanced non-small cell lung cancer. Lab Med Clin. 2022;19(8):1106-1108.
[8] Zhu XZ, Liu X, Li XT, et al. Efficacy and safety analysis of sintilimab combined with chemotherapy in the treatment of advanced non-small cell lung cancer. J Bengbu Med Univ. 2025;50(4):458-464. DOI:10.13898/j.cnki.issn.2097-5252.2025.04.008.
Copyright
© 2026 by the author(s).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited and is not modified or adapted.
https://creativecommons.org/licenses/by-nc-nd/4.0/
How to cite this paper
Efficacy and Safety Analysis of Sintilimab Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
How to cite this paper: Fushuang Qiao. (2026) Efficacy and Safety Analysis of Sintilimab Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. International Journal of Clinical and Experimental Medicine Research, 10(3), 241-244.
DOI: http://dx.doi.org/10.26855/ijcemr.2026.05.015